KORU Medical Systems Dirección

Dirección controles de criterios 3/4

KORU Medical Systems' El consejero delegado es Linda Tharby , nombrado en Apr 2021, tiene un mandato de 2.67 años. la remuneración anual total es $962.60K , compuesta por 57.1% salario y 42.9% primas, incluidas acciones y opciones de la empresa. posee directamente 2.31% de las acciones de la empresa, por valor de $2.43M . La antigüedad media del equipo directivo y del consejo de administración es de 1.8 años y 2.6 años respectivamente.

Información clave

Linda Tharby

Chief Executive Officer (CEO)

US$713.4k

Compensación total

Porcentaje del salario del CEO	78.9%
Permanencia del CEO	3yrs
Participación del CEO	3.9%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Feb 15

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Sep 21

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

Jul 14

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Aug 14

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Jan 27

KORU Medical Systems: A Razor & Razor Blade Story

Jan 11

Is Repro Med Systems, Inc. (NASDAQ:KRMD) Trading At A 50% Discount?

Dec 29

Have Insiders Been Buying Repro Med Systems, Inc. (NASDAQ:KRMD) Shares This Year?

Dec 03

The Independent Chairman of the Board of Repro Med Systems, Inc. (NASDAQ:KRMD), R. Fletcher, Just Bought 77% More Shares

Dec 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Linda Tharby en comparación con los beneficios de KORU Medical Systems?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$713k	US$563k	-US$14m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$1m	US$550k	-US$9m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$7m	US$398k	-US$5m

Compensación vs. Mercado: La compensación total de Linda ($USD713.37K) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD658.65K).

Compensación vs. Ingresos: Lindaha sido coherente con los resultados de la empresa en el último año.

CEO

Linda Tharby (55 yo)

3yrs

Permanencia

US$713,369

Compensación

Ms. Linda M. Tharby serves as President and Chief Executive Officer at KORU Medical Systems, Inc. (formerly known as Repro Med Systems, Inc.) since April 12, 2021 and serves as its Director since May 06, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Linda Tharby	President	3yrs	US$713.37k	3.91% $ 4.1m
Thomas Adams	CFO, Secretary & Treasurer	less than a year	US$555.40k	0.21% $ 223.0k
Brian Case	Chief Technology Officer	2yrs	US$371.16k	0.25% $ 264.8k
Kenneth Miller	Chief Commercial Officer	less than a year	US$717.22k	sin datos
Christopher Pazdan	Senior Vice President of Operations	2.3yrs	sin datos	sin datos
Rob Cannon	Vice President of Sales	3.3yrs	sin datos	sin datos

2.1yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: KRMDEl equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Linda Tharby	President	1.9yrs	US$713.37k	3.91% $ 4.1m
Edward Wholihan	Director	less than a year	US$28.10k	0.027% $ 28.5k
R. Fletcher	Independent Chairman of the Board	4.9yrs	US$140.00k	0.37% $ 388.8k
Robert Cascella	Independent Director	1.9yrs	US$125.00k	0.13% $ 132.9k
Joseph Manko	Lead Independent Director	8.2yrs	US$121.50k	0.35% $ 368.5k
Shahriar Matin	Independent Director	2.9yrs	US$110.00k	0.13% $ 139.6k
Donna French	Independent Director	2.9yrs	US$110.00k	0.13% $ 133.7k

2.9yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: KRMDno se consideran experimentados ( 2.6 años de permanencia media), lo que sugiere un nuevo consejo.

KORU Medical Systems Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

High number of new directors

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Recent updates

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024

KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic

KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Consensus EPS estimates upgraded to US$0.18 loss, revenue downgraded

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

New minor risk - Market cap size

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes

KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023

High number of new directors

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023

Price target decreased by 10% to US$4.33

KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled Syringes

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

KORU Medical Systems, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$4.83

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KORU Medical Revised Revenue Guidance for the Full Year of 2022

KORU Medical Systems, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

KORU Medical Systems, Inc. Revises Earnings Guidance for the Full Year 2022

KORU Medical Systems, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems Revises Earnings Guidance for the Year 2022

Price target decreased to US$4.67

Repro Med Systems, Inc. to Report Q1, 2022 Results on May 04, 2022

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Consensus forecasts updated

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Repro Med Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

Third quarter 2021 earnings released: US$0.025 loss per share (vs US$0.006 profit in 3Q 2020)

Price target decreased to US$4.67

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Second quarter 2021 earnings released: US$0.025 loss per share (vs US$0.027 loss in 2Q 2020)

Consensus forecasts updated

Consensus EPS estimates fall to -US$0.087

Repro Med Systems, Inc.(NasdaqCM:KRMD) dropped from Russell 3000 Growth Index

Independent Chairman of the Board recently bought US$108k worth of stock

First quarter 2021 earnings released: US$0.029 loss per share (vs US$0.011 profit in 1Q 2020)

The Portnoy Law Firm Advises the Investors About a Class Action Lawsuit Has Been Filed on Behalf of Repro-Med Systems, Inc. Investors

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit against Koru Medical Systems Investors

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Repro Med Systems, Inc. D/B/A Koru Medical Systems

Full year 2020 earnings released: US$0.029 loss per share (vs US$0.015 profit in FY 2019)

Repro Med Systems, Inc. Provides Revenue Guidance for the First Quarter Ending March 31, 2021

Repro Med Systems, Inc. Appoints Linda Tharby as President, Effective April 12, 2021

Repro Med Systems, Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: US$3.88

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

President & CEO Donald Pettigrew has left the company

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Price target lowered to US$8.88

Repro Med Systems, Inc. Announces Executive Changes

KORU Medical Systems: A Razor & Razor Blade Story

Is Repro Med Systems, Inc. (NASDAQ:KRMD) Trading At A 50% Discount?